Hubei Yuanda Tiantianming Pharmaceutical

Hubei Yuanda Tiantianming Pharmaceutical is a Chinese pharmaceutical company specializing in the research, development, manufacturing, and commercialization of ophthalmic formulations. Established in 2003 and acquired by Grand Pharma in 2010, the company serves as Grand Pharma's primary ophthalmic manufacturing base and is one of China's largest manufacturers of ophthalmic preparations. Its product portfolio includes a wide range of commercial eye drops and gels, such as Ruizhu (Polyvinyl Alcohol Eye Drops) for eye fatigue and Baitanting (Pirenoxine Sodium Eye Drops) for cataracts. Additionally, the company is advancing a robust pipeline of innovative ophthalmic therapies, including OC-01 for dry eye disease, TP-03 for Demodex blepharitis, and GPN00833 for post-operative inflammation.